Loading...

Gabe Ortiz, MD, PhD

TitleAssociate Professor
InstitutionUniversity of California San Francisco
DepartmentMedicine
AddressLocation Required
Varies CA 00000
Phone415-206-2355
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Yale Univeristy, New Haven, CTMS, BS1996Molecular Biophysics and Biochemistry
    Tri-Institutional MD, PhD Program, New York, NYMD, PhD2004Medicine and Human Immunology
    UCSF, San Francisco, CAResidency2007Internal Medicine
    UCSF, San Francisco, CAChief Residency2008Internal Medicine
    UCSF, San Francisco, CAFellowship2012Infectious Diseases

    Collapse Overview 
    Collapse Overview
    Gabriel Ortiz, MD, PhD, is an Assistant Clinical Professor at UCSF and a hospitalist at Zuckerberg San Francisco General. As the Medical Director of the Medical-Surgical Care Areas, he is focused on quality improvement work to enhance the care delivered to the vulnerable communities served by ZSFG. He is deeply engaged in applying Toyota's LEAN production and LEAN daily management systems as tools for achieving healthcare systems transformation (see links below for more information). Dr. Ortiz is also engaged in the implementation of Epic, the new enterprise EHR planned for ZSFG.


    Collapse ORNG Applications 
    Collapse Websites
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Haber LA, Ortiz GM. Clearing the air: inpatient providers' knowledge, perspectives, and experience with electronic cigarettes. J Hosp Med. 2014 Dec; 9(12):805-7. PMID: 25352497.
      View in: PubMed
    2. Seu L, Ortiz GM, Burt TD, Deeks SG, Martin JN, McCune JM. Levels of circulating myeloid subpopulations and of heme oxygenase-1 do not predict CD4(+) T cell recovery after the initiation of antiretroviral therapy for HIV disease. AIDS Res Ther. 2014; 11:27. PMID: 25180041; PMCID: PMC4150425.
      View in: PubMed, PubMed Central
    3. Seu L, Ortiz GM, Epling L, Sinclair E, Swainson LA, Bajpai UD, Huang Y, Deeks SG, Hunt PW, Martin JN, McCune JM. Higher CD27+CD8+ T cells percentages during suppressive antiretroviral therapy predict greater subsequent CD4+ T cell recovery in treated HIV infection. PLoS One. 2013; 8(12):e84091. PMID: 24391889; PMCID: PMC3877182.
      View in: PubMed, PubMed Central
    4. Brown JN, Ortiz GM, Angel TE, Jacobs JM, Gritsenko M, Chan EY, Purdy DE, Murnane RD, Larsen K, Palermo RE, Shukla AK, Clauss TR, Katze MG, McCune JM, Smith RD. Morphine produces immunosuppressive effects in nonhuman primates at the proteomic and cellular levels. Mol Cell Proteomics. 2012 Sep; 11(9):605-18. PMID: 22580588; PMCID: PMC3434775.
      View in: PubMed, PubMed Central
    5. Rakoff-Nahoum S, Kuebler PJ, Heymann JJ, E Sheehy M, Ortiz GM, S Ogg G, Barbour JD, Lenz J, Steinfeld AD, Nixon DF. Detection of T lymphocytes specific for human endogenous retrovirus K (HERV-K) in patients with seminoma. AIDS Res Hum Retroviruses. 2006 Jan; 22(1):52-6. PMID: 16438646.
      View in: PubMed
    6. Plana M, Garcia F, Oxenius A, Ortiz GM, Lopez A, Cruceta A, Mestre G, Fumero E, Fagard C, Sambeat MA, Segura F, Miró JM, Arnedo M, Lopalcos L, Pumarola T, Hirschel B, Phillips RE, Nixon DF, Gallart T, Gatell JM. Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3. J Acquir Immune Defic Syndr. 2004 Jul 01; 36(3):791-9. PMID: 15213562.
      View in: PubMed
    7. Alexander TH, Ortiz GM, Wellons MF, Allen A, Grace EJ, Schweighardt B, Brancato J, Sandberg JK, Furlan SN, Miralles GD, Nixon DF, Bartlett JA. Changes in CD4+ T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection. J Acquir Immune Defic Syndr. 2003 Dec 15; 34(5):475-81. PMID: 14657757.
      View in: PubMed
    8. Karlsson AC, Deeks SG, Barbour JD, Heiken BD, Younger SR, Hoh R, Lane M, Sällberg M, Ortiz GM, Demarest JF, Liegler T, Grant RM, Martin JN, Nixon DF. Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene. J Virol. 2003 Jun; 77(12):6743-52. PMID: 12767994; PMCID: PMC156163.
      View in: PubMed, PubMed Central
    9. García F, Plana M, Arnedo M, Ortiz GM, Miró JM, Lopalco L, Lori F, Pumarola T, Gallart T, Gatell JM. A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study. AIDS. 2003 Jan 03; 17(1):43-51. PMID: 12478068.
      View in: PubMed
    10. Schweighardt B, Ortiz GM, Grant RM, Wellons M, Miralles GD, Kostrikis LG, Bartlett JA, Nixon DF. Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. AIDS. 2002 Nov 22; 16(17):2342-4. PMID: 12441810.
      View in: PubMed
    11. Ortiz GM, Hu J, Goldwitz JA, Chandwani R, Larsson M, Bhardwaj N, Bonhoeffer S, Ramratnam B, Zhang L, Markowitz MM, Nixon DF. Residual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8+ T-cell responses in subjects treated early after infection. J Virol. 2002 Jan; 76(1):411-5. PMID: 11739706; PMCID: PMC135693.
      View in: PubMed, PubMed Central
    12. Ortiz GM, Wellons M, Brancato J, Vo HT, Zinn RL, Clarkson DE, Van Loon K, Bonhoeffer S, Miralles GD, Montefiori D, Bartlett JA, Nixon DF. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci U S A. 2001 Nov 06; 98(23):13288-93. PMID: 11687611; PMCID: PMC60863.
      View in: PubMed, PubMed Central
    13. García F, Plana M, Ortiz GM, Bonhoeffer S, Soriano A, Vidal C, Cruceta A, Arnedo M, Gil C, Pantaleo G, Pumarola T, Gallart T, Nixon DF, Miró JM, Gatell JM. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS. 2001 Jun 15; 15(9):F29-40. PMID: 11416735.
      View in: PubMed
    14. Bonhoeffer S, Rembiszewski M, Ortiz GM, Nixon DF. Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection. AIDS. 2000 Oct 20; 14(15):2313-22. PMID: 11089619.
      View in: PubMed
    15. Papasavvas E, Ortiz GM, Gross R, Sun J, Moore EC, Heymann JJ, Moonis M, Sandberg JK, Drohan LA, Gallagher B, Shull J, Nixon DF, Kostman JR, Montaner LJ. Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. J Infect Dis. 2000 Sep; 182(3):766-75. PMID: 10950770.
      View in: PubMed
    16. Binley JM, Schiller DS, Ortiz GM, Hurley A, Nixon DF, Markowitz MM, Moore JP. The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy. J Infect Dis. 2000 Apr; 181(4):1249-63. PMID: 10762561.
      View in: PubMed
    17. Ortiz GM, Nixon DF, Trkola A, Binley J, Jin X, Bonhoeffer S, Kuebler PJ, Donahoe SM, Demoitie MA, Kakimoto WM, Ketas T, Clas B, Heymann JJ, Zhang L, Cao Y, Hurley A, Moore JP, Ho DD, Markowitz M. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest. 1999 Sep; 104(6):R13-8. PMID: 10491418; PMCID: PMC408442.
      View in: PubMed, PubMed Central
    18. Gabriel M. Ortiz and David Graham.“Acinetobacter in military personnel.” Case vignette as part of www.antimicrobe.org.
      View Publication
    Gabe's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (87) concept(s)
    _
    Co-Authors
    People in Profiles who have published with this person.
    See all (8) people
    _
    Related Authors
    People who share related concepts with this person.
    See all (60) people
    _
    ↑